131 filings
8-K
SLRX
Salarius Pharmaceuticals, Inc.
15 Aug 24
Other Events
4:04pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
14 Aug 24
Other Events
4:09pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
25 Jul 24
Other Events
5:03pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
22 Jul 24
Other Events
5:39pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
19 Jul 24
Other Events
5:13pm
8-K
5c5seplt
11 Jul 24
Other Events
8:15am
8-K
h2mgb6kmw 15t8c1c6xo
17 Jun 24
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine
8:05am
8-K
z89pni6aar1 d1d4fu
14 Jun 24
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
4:04pm
8-K
jca0vd y7p5shvyty
6 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:02pm
8-K
sli8zoifd4i n6ohsui2
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
70flg4
6 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:09pm
8-K
jb5yi493
10 Aug 23
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
4:14pm
8-K
480h4zv
12 Jul 23
Other Events
9:22am
8-K
3tflb6wuckpf3
14 Jun 23
Departure of Directors or Certain Officers
6:47pm
8-K
noh058o2gept dp6c
16 May 23
Salarius Pharmaceuticals Announces $6 Million Private Placement
4:33pm
8-K
xfmqsn
13 Mar 23
Other Events
8:55am
8-K
xus u94v7elyy
10 Jan 23
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
11:11am
8-K
5fpbj
1 Dec 22
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
8:14am
8-K
cz17wkf
10 Nov 22
Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
8:38am
8-K
rc0x gukzurkkofe1aak
3 Nov 22
Other Events
9:28am